GeneDx Reports Incentive Grants Pursuant to Nasdaq Listing Rule 5635(c)(4) – September 27, 2024

STAMFORD, Conn.–(BUSINESS WIRE)–GeneDx (Nasdaq: WGS), a leader in improving health outcomes through genomic insights, today announced that GeneDx’s Board of Directors Compensation Committee has been appointed to a total of 7,700, effective September 23, 2024 Restricted Stock Units (“RSUs”) granted to two newly hired employees as incentive material for each employee who begins employment with GeneDx. The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

The Incentive RSUs vest in equal annual installments over four years from the grant date, subject to the employee’s continued service with the Company at each applicable vesting date. Each RSU represents a conditional right to receive one share of the issuer’s Class A common stock upon settlement.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe everyone deserves personalized, targeted healthcare – and that it all starts with a genetic diagnosis. Based on one of the world’s largest rare disease datasets, our industry-leading exome and genomic tests translate complex genomic data into clinical answers that enable personalized health plans, accelerate drug discovery and improve health system efficiency. Everything starts with a single test. For more information, please visit genedx.com and contact us at LinkedIn, X, FacebookAnd Instagram.

Contacts

Investor relations:
[email protected]

Media:
[email protected]